166 related articles for article (PubMed ID: 8880056)
1. Interindividual variability in catalytic activity and immunoreactivity of three major human liver cytochrome P450 isozymes.
Transon C; Lecoeur S; Leemann T; Beaune P; Dayer P
Eur J Clin Pharmacol; 1996; 51(1):79-85. PubMed ID: 8880056
[TBL] [Abstract][Full Text] [Related]
2. In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors.
Transon C; Leemann T; Dayer P
Eur J Clin Pharmacol; 1996; 50(3):209-15. PubMed ID: 8737761
[TBL] [Abstract][Full Text] [Related]
3. Cytochrome P4502B6 and 2C9 do not metabolize midazolam: kinetic analysis and inhibition study with monoclonal antibodies.
Hamaoka N; Oda Y; Hase I; Asada A
Br J Anaesth; 2001 Apr; 86(4):540-4. PubMed ID: 11573629
[TBL] [Abstract][Full Text] [Related]
4. Metabolism of dextromethorphan in vitro: involvement of cytochromes P450 2D6 and 3A3/4, with a possible role of 2E1.
Schmider J; Greenblatt DJ; Fogelman SM; von Moltke LL; Shader RI
Biopharm Drug Dispos; 1997 Apr; 18(3):227-40. PubMed ID: 9113345
[TBL] [Abstract][Full Text] [Related]
5. Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor.
Tang C; Shou M; Mei Q; Rushmore TH; Rodrigues AD
J Pharmacol Exp Ther; 2000 May; 293(2):453-9. PubMed ID: 10773015
[TBL] [Abstract][Full Text] [Related]
6. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2.
Ball SE; Ahern D; Scatina J; Kao J
Br J Clin Pharmacol; 1997 Jun; 43(6):619-26. PubMed ID: 9205822
[TBL] [Abstract][Full Text] [Related]
7. Evidence for involvement of polymorphic CYP2C19 and 2C9 in the N-demethylation of sertraline in human liver microsomes.
Xu ZH; Wang W; Zhao XJ; Huang SL; Zhu B; He N; Shu Y; Liu ZQ; Zhou HH
Br J Clin Pharmacol; 1999 Sep; 48(3):416-23. PubMed ID: 10510155
[TBL] [Abstract][Full Text] [Related]
8. Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cdna-expressed human cytochrome P450.
Ghosal A; Satoh H; Thomas PE; Bush E; Moore D
Drug Metab Dispos; 1996 Sep; 24(9):940-7. PubMed ID: 8886602
[TBL] [Abstract][Full Text] [Related]
9. CYP2C19 participates in tolbutamide hydroxylation by human liver microsomes.
Wester MR; Lasker JM; Johnson EF; Raucy JL
Drug Metab Dispos; 2000 Mar; 28(3):354-9. PubMed ID: 10681382
[TBL] [Abstract][Full Text] [Related]
10. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9.
Wen X; Wang JS; Backman JT; Kivistö KT; Neuvonen PJ
Drug Metab Dispos; 2001 Nov; 29(11):1359-61. PubMed ID: 11602509
[TBL] [Abstract][Full Text] [Related]
11. Characterization of dextromethorphan N-demethylation by human liver microsomes. Contribution of the cytochrome P450 3A (CYP3A) subfamily.
Gorski JC; Jones DR; Wrighton SA; Hall SD
Biochem Pharmacol; 1994 Jul; 48(1):173-82. PubMed ID: 8043020
[TBL] [Abstract][Full Text] [Related]
12. Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol.
Guitton J; Buronfosse T; Desage M; Flinois JP; Perdrix JP; Brazier JL; Beaune P
Br J Anaesth; 1998 Jun; 80(6):788-95. PubMed ID: 9771309
[TBL] [Abstract][Full Text] [Related]
13. Identification of human cytochrome P450 isoforms involved in the metabolism of S-2-[4-(3-methyl-2-thienyl)phenyl]propionic acid.
Taguchi K; Konishi T; Nishikawa H; Kitamura S
Xenobiotica; 1999 Sep; 29(9):899-907. PubMed ID: 10548450
[TBL] [Abstract][Full Text] [Related]
14. Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: inhibition by sulfaphenazole, omeprazole, and ticlopidine.
Giancarlo GM; Venkatakrishnan K; Granda BW; von Moltke LL; Greenblatt DJ
Eur J Clin Pharmacol; 2001 Apr; 57(1):31-6. PubMed ID: 11372587
[TBL] [Abstract][Full Text] [Related]
15. Hydroxylation and demethylation of the tricyclic antidepressant nortriptyline by cDNA-expressed human cytochrome P-450 isozymes.
Olesen OV; Linnet K
Drug Metab Dispos; 1997 Jun; 25(6):740-4. PubMed ID: 9193876
[TBL] [Abstract][Full Text] [Related]
16. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9).
Wen X; Wang JS; Kivistö KT; Neuvonen PJ; Backman JT
Br J Clin Pharmacol; 2001 Nov; 52(5):547-53. PubMed ID: 11736863
[TBL] [Abstract][Full Text] [Related]
17. Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes.
Yamazaki H; Shimada T
Arch Biochem Biophys; 1997 Oct; 346(1):161-9. PubMed ID: 9328296
[TBL] [Abstract][Full Text] [Related]
18. In vitro metabolism of quinidine: the (3S)-3-hydroxylation of quinidine is a specific marker reaction for cytochrome P-4503A4 activity in human liver microsomes.
Nielsen TL; Rasmussen BB; Flinois JP; Beaune P; Brosen K
J Pharmacol Exp Ther; 1999 Apr; 289(1):31-7. PubMed ID: 10086984
[TBL] [Abstract][Full Text] [Related]
19. Characterization of transgenic mouse strains using six human hepatic cytochrome P450 probe substrates.
Mankowski DC; Lawton MP; Ekins S
Xenobiotica; 2000 Aug; 30(8):745-54. PubMed ID: 11037108
[TBL] [Abstract][Full Text] [Related]
20. The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase.
Crespi CL; Miller VP
Pharmacogenetics; 1997 Jun; 7(3):203-10. PubMed ID: 9241660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
